Solitary mandibular recurrence of uterine endometrial carcinoma successfully treated with chemotherapy alone: A case report.

BACKGROUND

Recurrence of endometrial carcinoma typically occurs in the pelvic region, with the lungs and lymph nodes being common sites for distant metastasis. However, recurrence involving the head and neck region is exceedingly rare.

CASE PRESENTATION: We report a case of solitary mandibular recurrence of endometrial carcinoma successfully treated with lenvatinib and pembrolizumab. A 56-year-old woman was diagnosed with stage II clear cell carcinoma of the uterus. She underwent total abdominal hysterectomy, bilateral adnexectomy, partial omentectomy, appendectomy, pelvic and para-aortic lymphadenectomy. Postoperative adjuvant chemotherapy with six cycles of paclitaxel and carboplatin was administered, followed by observation. Two months after the completing of treatment, the patient developed trismus and pain in the left mandible. Imaging studies revealed a 4 cm mass in the left mandible. Needle biopsy confirmed a solitary recurrence of endometrial carcinoma. After the administration of pembrolizumab and lenvatinib therapy, the tumor was no longer detectable, which has been maintained.

CONCLUSION

Mandibular metastasis from endometrial carcinoma is extremely rare and may mimic primary jaw tumors. Treatment options include surgical resection, radiotherapy, and systemic therapy. A comprehensive evaluation of the primary tumor status, presence of other metastases, and the patient's functional condition is essential for determining the optimal therapeutic strategy.